SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a focal point of market discussion, primarily driven by the ongoing, contentious acquisition saga surrounding Warner Bros. Discovery, which continues to generate significant uncertainty. This prolonged situation, compounded by mixed analyst sentiment, has led to sharply divided investor opinions, with many debating the stock's "oversold" status as it navigates a challenging environment ahead of its earnings report.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is a major talking point as the bank kicks off earnings season, with community discussions intensely focused on recent warnings about rising expenses and the potential impact of a proposed credit card interest rate cap. Investors are also digesting the bank's strategic move to take over the Apple Card program and its deeper foray into blockchain and tokenized funds, all while online chatter includes speculation regarding its market positions in commodities.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is gaining attention following a new pre-production order for GPU-accelerated systems for U.S. Army combat vehicles, which is amplifying community anticipation for a much larger defense contract in the burgeoning Edge AI sector. Investors are bullish on the company's focused strategy after a recent asset sale, coupled with its specialized technology, low stock float, and potential for significant growth in defense and AI infrastructure. Discussions highlight the company's strong positioning for future defense spending and AI compute needs at the tactical level.

KOLANA is a koala-character meme coin that has been designed as the newest meme character token to join the Solana ecosystem. It’s a fun, community-driven token with no inherent value, created purely for those who want to participate in the Solana meme culture and become a part of the KOLANA community. While it doesn't offer utility or financial promises, it thrives on community engagement and decentralised fun.

KOLANA

KOLANA CRYPTO is capturing significant community interest, driven by discussions around its clear technical levels and steady momentum. Many are expressing enthusiasm for potential early entry, indicating a growing speculative sentiment around the asset.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company is trending strongly, fueled by a significant uplift in lithium prices and robust community enthusiasm for 'made in USA' battery recycling and critical mineral plays. Investors are closely watching its operational advancements, including the claystone to hydroxide plant and progress on major recycling contracts, anticipating further government support and strong future earnings. The bullish sentiment reflects expectations that ABAT is positioned to capitalize on the growing domestic demand for battery materials.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics (TVTX) is generating intense market conversation and significant volatility due to a recent FDA request for additional data to further characterize FILSPARI's clinical benefit for its potential FSGS indication, despite the company reiterating confidence and reporting robust sales for its existing IgAN approval. This immediate uncertainty has polarized the community, with many speculating on a Complete Response Letter (CRL) while others perceive the sharp sell-off as an overreaction, viewing it as a buying opportunity given the high unmet medical need in FSGS.

Lulu's Fashion Lounge Holdings, Inc. engages in providing an online website for clothing. It offers retailing of women's clothing, shoes, and accessories. The company was founded in 1996 and is headquartered in Chico, CA.

Lulus Fashion Lounge Holdings Inc

Lulus Fashion Lounge (LVLU) is trending due to activist investor Christian Friedland's disclosed stake and call for significant governance reforms, emphasizing the company's "extremely undervalued" status. The community is actively discussing Friedland's assertion that LVLU trades at a 27x valuation gap compared to peers, despite achieving positive adjusted EBITDA and expanded gross margins. This has ignited speculation among traders about a potential "super squeeze" and multi-day run, driven by the proposed reforms and perceived undervaluation.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix is experiencing significant upward momentum following preliminary Q4 and full-year 2025 results that exceeded guidance, showing strong revenue growth. This positive update, coupled with its small float, is fueling intense discussion among traders actively debating its breakout potential and the possibility of a short squeeze, despite ongoing concerns about future dilution.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is actively trending as its passionate community rallies behind its audacious goal to become the top memecoin, aiming to surpass established players like Dogecoin. Discussions highlight its deflationary token burns and strong presence across the Solana and Cronos chains, driving fervent "bullish" sentiment despite some skepticism.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as new iGaming legalizations, notably in Maine, and ongoing discussions in other states like New York and Virginia, signal expansion opportunities. The community is actively debating the impact of its recently launched prediction markets platform, while many anticipate strong engagement and revenue from the upcoming NFL playoffs and Super Bowl. This growth is viewed against persistent frustrations over the stock's current valuation despite underlying business momentum and ongoing efforts to expand its regulated online betting footprint.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that it will attend the JP Morgan 2026 Annual...

Credit-Card Sized Device Wins FDA Clearance for At-Home Heart Monitoring

Cardiac care is undergoing a fundamental shift as technology enables patients to capture critical health data outside traditional medical settings. The ability to record meaningful cardiac information during symptomatic episodes, rather than hours or days later in a doctor's office, represents a paradigm change in how physicians diagnose and manage heart conditions affecting millions of Americans.Shares of HeartBeam, Inc. (NASDAQ: BEAT) are surging Wednesday after the company announced FDA 510(k) clearance for its groundbreaking 12-lead electrocardiogram (ECG) synthesis software for ...

<ul class="summary-bullets"><li>The clearance enables HeartBeam’s cable-free technology to capture the heart’s electrical signals in three dimensions.</li><li>The approval follows a successful appeal of a prior Not Substantially Equivalent (NSE) determination.</li><li>The company intends to roll out a controlled commercial launch in early 2026.</li></ul>HeartBeam, Inc. (BEAT) on Wednesday announced that the U.S. Food and Drug Administration (FDA) has cleared its 12-lead electrocardiogram (ECG) synthesis software for arrhythmia assessment, which enables its cable-free technology to capture the heart’s electrical signals in three dimensions and convert them into a complete 12-lead ECG.The approval follows a successful appeal of a prior Not Substantially Equivalent (NSE) determination, marking a significant milestone for the company.<h2 class="st-heading-2">Why It Matters?</h2>Unlike traditional single-lead or 6-lead devices, this innovation allows patients to obtain accurate cardiac readings from home, with synthesized results promptly reviewed by board-certified cardiologists.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/BEAT">HeartBeam’s stock</a> traded over 72% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day, while message volume shifted to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<blockquote>“We look forward to initiating our U.S. market introduction while advancing our efforts on heart attack detection, an on-demand 12-lead extended wear patch, and AI-based screening and prediction algorithms trained on our unique longitudinal data.”-Robert Eno, CEO, HeartBeam</blockquote><h2 class="st-heading-2">Limited U.S. Launch Planned</h2>The company intends to roll out a controlled commercial launch in early 2026, targeting select concierge and preventive cardiology groups that have expressed strong interest.&nbsp;It has developed a working prototype of an extended-wear 12-lead ECG patch, designed to provide continuous cardiac monitoring. As HeartBeam’s 3D ECG platform adoption grows, the resulting data repository will enable longitudinal analysis. The company plans to use this data to develop AI-based screening and predictive algorithms.BEAT stock has lost over 64% in 2025 and over 73% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lucid-signals-tough-road-ahead-amid-slumping-ev-demand-ceo-says-there-is-a-slowdown-there-s-no-question-about-it/cLIHRZWRENx">Lucid Signals Tough Road Ahead Amid Slumping EV Demand: CEO Says ‘There Is A Slowdown, There’s No Question About It’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Atrial tachycardia electrocardiogram, heart rhythm disorder where the patient complains of rapid palpitation sensations.

Why Did BEAT Stock Rocket 72% In Pre-Market Today? 

The FDA has cleared HeartBeam’s 12-lead electrocardiogram synthesis software for arrhythmia assessment.

Equity

The FDA has cleared HeartBeam’s 12-lead electrocardiogram synthesis software for arrhythmia assessment.


What's Behind HeartBeam's Over 40% After-Hours Surge?

HeartBeam shares jumped 40.75% in after-hours trading after the company outlined its regulatory strategy following the FDA's Not Substantially Equivalent decision.read more...

HeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software Application

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced its regulatory strategy following...

<ul class="summary-bullets"><li>Roth Capital sees potential FDA clearance for the software.</li><li>The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, the analyst said.&nbsp;</li><li>HeartBeam is now evaluating launching its 3D ECG system, which received FDA clearance in December 2024.</li></ul>Shares of HeartBeam, Inc. (BEAT) slumped 58% on Friday afternoon after the company said that the U.S. Food and Drug Administration refused clearance for its 12-Lead Electrocardiogram (ECG) Synthesis Software for arrhythmia assessment.The medical technology company said that it received a ‘not substantially equivalent’ letter from the FDA. A "Not Substantially Equivalent" (NSE) letter is an official notification from the FDA stating that a new medical device is not considered substantially equivalent to a legally marketed predicate device.The company said that it will be working with the agency to get to a resolution and expressed confidence in its clinical data. Earlier this month, HeartBeam had touted FDA clearance for the software as a major inflection point for the company.The company is now evaluating launching its 3D ECG system which received FDA clearance in December 2024.<h2 class="st-heading-2">Analyst Takeaway</h2>Roth Capital, however, sees potential FDA clearance for the software. The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, it said.While resolving the pathway for the 12-lead ECG synthesis software, management may decide to roll out the foundational 3D ECG system to concierge medical practices, preventive cardiology clinics, and hospital-at-home programs, the analyst said, as per The Fly.The analyst kept a ‘Buy’ rating on HeartBeam with a $4 price target. The price target represents a potential upside of over 138% from the stock’s closing price on Thursday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BEAT">BEAT stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user echoed Roth Capital’s opinion and said that the stock would beat $5 on FDA approval.<stembedurl>https://stocktwits.com/jamestocklover/message/637108009</stembedurl>Another noted that an NSE letter is not the end.<stembedurl>https://stocktwits.com/Rolltide2020/message/637103348</stembedurl>BEAT stock is down by 70% this year and by about 75% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/will-scot-stock-surges-after-baird-upgrade-analyst-calls-q3-a-watershed-quarter/cLPMv4RREfb">WillScot Stock Surges After Baird Upgrade – Analyst Calls Q3 A ‘Watershed Quarter’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

HeartBeam Stock Slumps After FDA Refuses Clearance For ECG Software

The company said it will work with the agency to reach a resolution and expressed confidence in its clinical data.

HeartBeam Reports Third Quarter 2025 Results

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for...

HeartBeam Earnings Preview

HeartBeam to Host Third Quarter 2025 Results Conference Call on Thursday, November 13, 2025 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, November 13...

HeartBeam Teams Up With HeartNexus to Deliver Cardiologist-Level ECG Insights Anytime, Anywhere

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced a partnership with HeartNexus, Inc., a...

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

HeartBeam Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

BEAT
HeartBeam Inc

Feed

News

Sentiment

Fundamentals

Info

Latest BEAT News

BEATHeartBeam Inc